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Abstract
Background: HIV transmitted drug resistance (TDR) is a public health concern because it has the potential to compromise
antiretroviral therapy (ART) at the population level. In New York State, high prevalence of TDR in a local cohort and a
multiclass resistant case cluster led to the development and implementation of a statewide resistance surveillance system.
Methodology: We conducted a cross-sectional analysis of the 13,109 cases of HIV infection that were newly diagnosed and
reported in New York State between 2006 and 2008, including 4,155 with HIV genotypes drawn within 3 months of initial
diagnosis and electronically reported to the new resistance surveillance system. We assessed compliance with DHHS
recommendations for genotypic resistance testing and estimated TDR among new HIV diagnoses.
Principal Findings: Of 13,109 new HIV diagnoses, 9,785 (75%) had laboratory evidence of utilization of HIV-related medical
care, and 4,155 (43%) had a genotype performed within 3 months of initial diagnosis. Of these, 11.2% (95% confidence
interval [CI], 10.2%–12.1%) had any evidence of TDR. The proportion with mutations associated with any antiretroviral agent
in the NNRTI, NRTI or PI class was 6.3% (5.5%–7.0%), 4.3% (3.6%–4.9%) and 2.9% (2.4%–3.4%), respectively. Multiclass
resistance was observed in ,1%. TDR did not increase significantly over time (p for trend = 0.204). Men who have sex with
men were not more likely to have TDR than persons with heterosexual risk factor (OR 1.0 (0.77–1.30)). TDR to EFV+TDF+FTC
and LPV/r+TDF+FTC regimens was 7.1% (6.3%–7.9%) and 1.4% (1.0%–1.8%), respectively.
Conclusions/Significance: TDR appears to be evenly distributed and stable among new HIV diagnoses in New York State;
multiclass TDR is rare. Less than half of new diagnoses initiating care received a genotype per DHHS guidelines.
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Introduction
The widespread use of anti-retroviral therapy (ART) and the
extended survival of HIV-infected individuals have produced a
growing population of ART-experienced persons who may
develop antiretroviral (ARV) drug resistance. Individuals with
ARV resistance have reduced responsiveness to ART, delayed or
incomplete viral suppression and poor outcomes [1,2]. Moreover,
they may transmit resistant infection to others. Transmitted drug
resistance (TDR) is a public health concern because it has the
potential to compromise ART at the population level. In New
York State, a report of increasing TDR in a local cohort [3] and a
case cluster involving transmission of a multi-class resistant virus
[4–6] suggested the need to monitor TDR statewide. In 2005,
building on existing HIV surveillance, which already included
routine reporting of viral loads, CD4 counts and positive Western
blots, [7–10] New York State introduced mandatory electronic
reporting of viral nucleotide sequences for the purpose of
conducting resistance surveillance [11,12]. We report results of
the first three years of data from the New York State resistance
surveillance system, the first of its kind in the U.S.
Methods
Data Sources
The HIV/AIDS surveillance systems of the New York State
Department of Health (NYSDOH) and the New York City
Department of Health and Mental Hygiene (NYC DOHMH)
have been described previously [13–15]. Nucleotide sequences
from HIV genotypes, along with other HIV-related tests and
conditions, are reportable by law [7–12]. Laboratory and provider
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reports are transmitted to NYSDOH where they are matched to
the New York State HIV registry; data relating to cases within
New York City are forwarded to NYC DOHMH where they are
matched to the NYC HIV registry. Incoming data at the state or
city level that do not match an existing registry record initiate a
field investigation to confirm the case, date and disposition of
diagnosis and collect other data required by surveillance. An
analysis dataset was created based on diagnoses and laboratory
results dated January 1, 2006, through December 31, 2008,
reported by April 30, 2010, and added to the NYS HIV registry as
of May 31, 2010. A total of 14,046 persons aged 13 and older and
not perinatally infected had an initial diagnosis date between
January 1, 2006, and December 31, 2008; 937 (6.7%) were
excluded because of missing or discrepant data on date of initial
diagnosis or genotype, leaving 13,109 for analysis.
Data definitions
Diagnosis refers to a new diagnosis of HIV with or without a
concurrent diagnosis of AIDS. Concurrent diagnosis was defined
as AIDS diagnosis within 31 days of initial diagnosis of HIV.
Region at diagnosis was categorized as New York City or New
York State excluding New York City. Poverty area was defined as
residence at diagnosis in a ZIP code tabulation area in which at
least 20% of residents per US Census 2000 met the federal
definition of poverty. Poverty area was not calculated for homeless
or sheltered persons or for persons residing in zip codes created
after 2000. Cases with missing risk factor were assigned to the
category, ‘‘no identified risk.’’ Initial resistance test was defined as
the first HIV genotype (if any) within 3 months of diagnosis. The
3 month interval was chosen to limit the number of persons that
may have started ART before resistance testing and to allow
comparison with results from the Centers for Disease Control’s
(CDC) Variant, Atypical, and Resistant HIV Surveillance
(VARHS) system [16–17]. In addition to nucleotide sequences,
laboratory data included the first CD4 count and viral load drawn
within 3 months of diagnosis. Persons with a viral load, CD4 count
or resistance test within 3 months of diagnosis were considered in
care because these tests must be ordered by a physician [14]. CD4
counts were dichotomized as .350 cells/ml or ,350 cells/ml
because Department of Health and Human Services (DHHS)
guidelines in place during the reporting period recommended
initiation of ART at this threshold [18]. Viral loads were grouped
into three intervals, ,10,000 copies/ml, 10,000–100,000 copies/
ml, and .100,000 copies/ml.
Resistance Analysis
HIV genotype testing was performed by commercial laborato-
ries using various test kits, including ViroseqTM, GenoSureTM,
TRUGENETM and in-house kits. Only protease and reverse
transcriptase sequences of the pol gene were reported. Nucleotide
sequences were analyzed using the Resistance Analysis System
(RAS), version 2.0 (Frontier Science & Technology Research
Foundation, Amherst, New York), a program built specifically to
facilitate NYS resistance surveillance. Mutations were ascertained
by a comparison of aligned sequences with the Los Alamos
National Laboratory subtype B consensus sequence [19]. ARV-
specific predicted resistance was calculated using code developed
by Frontier Science and scores from the Stanford HIVDB
algorithm, version 6.0.9; [20,21] this algorithm was also used to
determine HIV-1 subtype. Sequences that did not meet the
minimum processing requirement of the HIVDB algorithm could
not be analyzed [20].
Transmitted drug resistance was defined as the presence of 1 or
more mutations in the surveillance drug resistance mutation list
(SDRM) [22]. ARVs were categorized by class. Single, double or
triple class resistance was defined as 1 or more surveillance drug
mutation within one, two or three antiretroviral drug classes
respectively. Predicted resistance to specific antiretroviral drugs
was defined as sequences with a score of $4 on the Stanford
HIVDB 5-point resistance scale [20].
Statistical Analysis
Multivariate logistic regression was used to assess the likelihood
of an initial resistance test and the likelihood of TDR as a function
of demographic and clinical characteristics. Unadjusted and
adjusted odd ratios with 95% confidence intervals (CIs) were
calculated. Concurrent diagnosis of HIV/AIDS was excluded
from the regression analysis of testing patterns because it is
partially defined by CD4 count. Variables significant (p,0.05) on
bivariate analysis were entered into multivariate logistic regression
models for the two outcome variables, testing and TDR.
Confidence limits for proportions were calculated using exact
CIs for the binomial proportion. Trends were examined using the
Cochran-Armitage test and are reported with two-sided p-values.
All statistical tests were performed using SAS, version 9.1.3 (SAS
Institute, Cary, North Carolina).
Results
Population Demographics and Resistance Testing
Patterns
Of the 13,109 persons included in the analysis, 4,155 (31.7%)
received their first resistance test within 3 months of diagnosis
(‘‘initial resistance test’’); 1,311 (10.0%) were first genotyped .3–
12 months after diagnosis, 7,643 (13.3%) were first genotyped
.12 months after diagnosis, and 44.9% were never genotyped. Of
all persons ever genotyped, three-quarters were genotyped within
three months of initial diagnosis. Patients never genotyped differed
significantly from patients ever genotyped by age, race, risk factor,
and disease stage at diagnosis (data not shown). Patients with
CD4,350, VL.100,000 and concurrent HIV/AIDS at diagno-
sis, i.e., patients meeting DHHS guidelines for ART, were more
likely to have ever been genotyped.
Initial resistance testing among newly diagnosed persons
differed significantly by sex, race/ethnicity, age, risk factor, region
of diagnosis, poverty area, year of diagnosis, and disease stage at
diagnosis (Table 1). Among persons with new diagnoses, 9,785
(74.6%) showed evidence of care (i.e., saw a physician) within
3 months of diagnosis. Of persons in care, 4,155 (43%) had initial
resistance tests. Among all newly diagnosed, the proportion with
an initial resistance test increased from 25% in 2006 to 38% in
2008 (p for trend ,0.0001). Subsequent analyses were conducted
among persons in care within three months (N = 9,785 or 74.6%
of the total number of newly diagnosed) because these would be
the only persons in the database who would have had the
opportunity for initial resistance testing.
In the multivariate analysis of initial resistance testing among
newly diagnosed persons in care, blacks and Hispanics were less
likely to be tested than whites (AOR 0.70 (0.61–0.79), AOR 0.85
(0.74–0.97)) (Table 1). Persons aged 13–24 or 40–59 at diagnosis
were slightly less likely to be tested than those 25–39 (AOR 0.77
(0.67–0.89); AOR 0.87 (0.79–0.97)), while persons 60 and older
were no more likely to be tested (AOR 0.96 (0.79–1.19)).
Compared with men who have sex with men (including men
who have sex with men and use injection drugs (MSM + MSM/
IDU)), persons with heterosexual transmission risk were less likely
to be tested (AOR 0.77 (0.66–0.90)).
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All 450 11.2 4032
Sex 0.679
Male 332 11.0 3007 Referent
Female 118 11.5 1025 1.05 (0.84–1.31)
Race/Ethnicity 0.346
Black 164 10.1 1620 0.78 (0.61–1.01)
Hispanic 140 11.7 1198 0.92 (0.71–1.19)
White 123 12.6 979 Referent
Asian/Pacific
Islander
12 9.7 124 0.75 (0.40–1.39)
Native
American/Multirace
11 9.9 111 0.77 (0.40–1.47)
Age at Diagnosis 0.014 0.078
13–24 78 14.3 544 1.26 (0.95–1.67) 1.22 (0.91–1.61)
25–39 199 11.7 1698 Referent Referent
40–59 150 9.5 1584 0.79 (0.63–0.99) 0.83 (0.66–1.04)
60+ 23 11.2 206 0.95 (0.60–1.50) 1.06 (0.66–1.69)
Risk 0.002 0.010
MSM (+MSM/IDU) 242 12.6 1922 Referent Referent
IDU 17 8.7 195 0.66 (0.40–1.11) 0.74 (0.44–1.25)
Heterosexual 85 12.6 676 1.00 (0.77–1.30) 1.03 (0.79–1.35)
No Identified Risk 106 8.6 1239 0.65 (0.51–0.83) 0.68 (0.53–0.87)
Residence at diagnosis 0.905
City 317 11.1 2850 Referent
Rest of State 133 11.3 1182 1.01 (0.82–1.26)
Poverty 0.770
Non-poverty Area 228 11.1 2052 Referent
Poverty Area 207 10.8 1913 0.97 (0.80–1.18)
Missing zip 15 22.4 67
Year of diagnosis 0.011 0.022
2006 123 11.5 1073 Referent Referent
2007 123 9.2 1344 0.78 (0.60–1.01) 0.79 (0.60–1.03)
2008 204 12.6 1615 1.12 (0.88–1.42) 1.10 (0.86–1.40)
Clinical stage at diagnosis
HIV only 281 11.7 2401
HIV/AIDS 169 10.4 1631
CD4 count 0.217
,350 253 10.6 2389 Referent
. = 350 171 11.9 1439 1.14 (0.93–1.40)
Missing CD4 26 12.7 204
VL 0.593 0.765
,10,000 124 13.9 892 1.61 (0.74–3.49) 1.50 (0.69–3.29)
10,000–100,000 164 10.2 1607 1.09 (0.88–1.35) 1.02 (0.82–1.27)
. = 100,000 137 10.6 1292 Referent Referent
Missing VL 25 10.4 241 0.98 (0.62–1.53) 0.95 (0.60–1.50)
*Multivariate logistic regression excludes cases with missing data except for missing risk which is categorized at ‘‘No identifiable risk’’.
doi:10.1371/journal.pone.0040533.t002
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Persons diagnosed in New York State excluding New York City
were more likely to have a resistance test than persons diagnosed
in New York City (AOR 1.25 (1.11–1.40)), as were persons
diagnosed in 2008 in comparison to those diagnosed in 2006
(AOR 1.85 (1.66–2.06)). Persons living in a non-poverty area were
not significantly more likely to have a resistance test than those
living in a poverty area (AOR 0.93 (0.85–1.03)). Persons with
initial CD4 count $350 cells/ml were less likely to have a
resistance test than persons with CD4 count ,350 cells/ml (AOR
0.57 (0.51–0.62)), and persons with viral loads of ,10,000 copies/
mL or 10,000–100,000 copies/mL were less likely to have a
resistance test than persons with .100,000 copies/mL (AOR 0.14
(0.10–0.19), AOR 0.85 (0.77–0.95)).
Resistance patterns
Of the 4,155 initial resistance tests, 123 were reported with
partial nucleotide sequences, and 4,032 (97.0%) had analyzable
sequences. Among these, 450 (11.2% (10.2%–12.1%)) had
evidence of TDR (Table 2). TDR did not significantly increase
over time (p for trend = 0.204). In the multivariate analysis, risk,
year of diagnosis and viral load remained significantly associated
with TDR., However persons with a heterosexual risk factor were
no more likely to have resistance than MSM (AOR 1.03 (0.79–
1.35)). In addition, black and Hispanic MSM were no more likely
to have TDR in comparison with other race and risk groups (OR
1.10 (0.82–1.49) data not shown). Persons with no identified risk
(NIR) were significantly less likely to have TDR than MSM (AOR
0.68 (0.53–0.87)).
TDR varied by drug class. Resistance was highest to NNRTIs
(6.3% (5.5%–7.0%)) and was significantly higher than resistance to
NRTIs (4.3% (3.6%–4.9%)) and PIs (2.9% (2.4%–3.4%)) (Table 3).
Over time, there was no significant increase in resistance in the
NNRTI, NRTI or PI classes (p = 0.144, p = 0.686, p = 0.851,
respectively). Resistance in two classes was highest in the NRTI-
NNRTI (0.8%) combination; resistance in three classes was
minimal (,0.5%). The most frequently observed polymorphisms
by drug class are shown in Table 4.
We also examined predicted resistance to 1 or more compo-
nents of selected starting regimens recommended by DHHS [18].
Resistance to 1 or more ARVs within the NNRTI-inclusive
regimen EFV+TDF+FTC was observed in 7.1% (6.3%–7.9%) of
cases (data not shown). In contrast, 1.4% (1.0%–1.8%) were
resistant to 1 or more drugs in the PI-inclusive regimen LPV/
r+TDF+FTC. Among individual NRTIs, resistance was highest to
AZT and D4T (1.8% (1.4%–2.2%) and 1.6% (1.2%–2.0%)) and
lower to TDF (0.3% (0.1%–0.5%) and FTC (0.9% (0.6%–1.2%),
the two agents with recently demonstrated efficacy in pre-exposure
prophylaxis [23]. 3TC, which in the treatment setting can be used
interchangeably with FTC, showed similarly low resistance (0.9%
(0.6%–1.2%)).
Most analyzed sequences (92.8%) were subtype B; 118 (2.9%)
were CRF02_AG; and 83 (2.1%) were subtype C. Persons residing
in NYC at diagnosis were no more likely to have non-B subtypes
than persons residing in New York State excluding New York City
(7.7% vs. 6.0%, p = 0.0611).
Discussion
Resistance Testing Patterns
Within the U. S., this analysis represents the first use of routinely
reported surveillance data to estimate TDR and to describe
resistance testing patterns as well as the largest number of
sequences used for resistance surveillance to date [16,24]. More
than half of newly diagnosed persons who entered care within
three months did not receive an initial resistance test per DHHS
guidelines, although the proportion receiving initial resistance tests
increased between 2006 and 2008. The observed increase is
consistent with the adoption of the 2007 DHHS guidelines
recommending resistance testing for all newly diagnosed persons
[18,25]. Previous guidelines recommended resistance testing for
acute infection and patients initiating or failing ART [23].
Significant differences in resistance testing by demographic
characteristics, including race, age and transmission risk, are
concordant with literature on initiation, source, and utilization of
care [26–28]. Potential candidates for initiation of ART per
DHHS guidelines (CD4,350) were more likely to be tested than
others, likely reflecting the decision by some providers to postpone
resistance testing until initiation of ART. Similarly, persons with
low viral loads (,10,000) were less likely to be tested. While this
could be evidence of the impact of viral load on a provider’s
decision to genotype, it may also be affected by the failure of
amplification and genotyping at low viral loads (failed genotypes
are not reported). Resistance testing was less common among
NYC residents than residents in the rest of the state, an
unexpected finding given the concentration of training hospitals
and designated AIDS centers in the city. Further analysis is needed
Table 3. Transmitted Drug Resistance by drug class. New
York State 2006–2008.
Total
N % 95% CI
Genotypes Analyzed 4032 -
Any 450 11.2% 10.2% 12.1%
NRTI 172 4.3% 3.6% 4.9%
NNRTI 252 6.3% 5.5% 7.0%
PI 116 2.9% 2.4% 3.4%
Two Class
NRTI-NNRTI 33 0.8% 0.5% 1.1%
NRTI-PI 15 0.4% 0.2% 0.6%
NNRTI-PI 16 0.4% 0.2% 0.6%
Three Class
NRTI-NNRTI-PI 13 0.3% 0.1% 0.5%
doi:10.1371/journal.pone.0040533.t003
Table 4. Top 10 mutations by drug class.
rank NRTI Mutation NNRTI Mutation PI Mutation
1 G333E K103N L10I
2 V118I E138A A71T
3 M41L K103R L10V
4 T69N V179D A71V
5 G333D K101Q L10IL
6 T215D G190A L90M
7 G333EG V179E A71AT
8 M184V V108I T74S
9 D67N K103KR A71AV
10 V118IV Y181C V11I
doi:10.1371/journal.pone.0040533.t004
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to elucidate the relationship between resistance testing, provider
type, and utilization of care.
Transmitted Drug Resistance
The prevalence of TDR among persons with new diagnoses in
NYS in 2006–2008 was 11.2% (10.2%–12.1%). There was no
significant change in TDR over time. Worldwide estimates of
TDR range from 8%–24%, though comparison between these
results is difficult due to differences in the mutations used to define
TDR [29–38]. Our estimate, based on the SDRM list [22], is
higher than the national prevalence estimate (8.3%) for the time
period 1997–2001 [39] but is substantially lower than a previous
report of resistance in a NYC sample of MSM in 2003–2004
(24.1%) [3]. Both of these studies used modified IAS-USA
mutation lists. Wheeler et al. estimated the national prevalence
of transmitted drug resistant mutations (TDRM) in 2006 to be
14.6% using a modified SDRM list [16]. We estimated the New
York State TDR to be 24.2% using the same mutation list (results
not shown). Further analysis is needed to test the utility of the
SDRM and TDRM lists in the U.S. epidemic.
In contrast to previous findings of increasing TDR and high
levels of TDR among MSM, we found stable resistance evenly
distributed between MSM and heterosexual risk groups [3,40].
Better risk factor ascertainment would allow us to measure the
TDR by risk factor more accurately and/or to understand the
unexpected findings of this analysis. Our data show that 1 in 9
persons newly diagnosed with HIV in NYS has TDR and 1 in 50
is predicted to have a suboptimal response to a standard ART
regimen. Key populations considered to be on the leading edge of
the epidemic, e.g., young black and Hispanic MSM, showed no
more TDR than others. Ongoing surveillance will confirm the
significance and durability of these observations.
Limitations
Our analysis has important limitations. HIV surveillance data
contain limited person-level information; duration of infection and
ART history are not available. Newly-diagnosed persons are
assumed to be ARV-naı̈ve but may not be. Despite the CDC-
sponsored routine interstate duplication review (RIDR) and
comprehensive field investigation, persons may be incorrectly
identified as newly diagnosed because there is incomplete date
information or because they were diagnosed out of state and
subsequently received HIV care in New York State. In such cases
acquired resistance may be incorrectly classified as TDR. The
number of resistance tests reported is an underestimate of the
number ordered by providers because resistance tests in which
viral RNA amplification fails are not reportable.
Integrating resistance data into the existing surveillance system
was logistically and technically challenging. Laboratories certified
by NYSDOH to perform resistance testing were required to report
nucleotide sequences beginning on June 1, 2005. However,
laboratories acquired full capacity to report resistance data at
different times after the regulations were enacted, which meant
that much of the data was reported retrospectively. Laboratories
were required to resubmit when incomplete data were identified;
however, some laboratories were not able to do so. Completeness
of laboratory reporting was estimated by comparing self-reported
laboratory testing logs to received data transmissions. Complete-
ness was estimated to be 82% in 2006, 89% in 2007, and 98% in
2008. Adjusting for completeness, the proportion of persons with
new diagnoses with initial resistance tests increased from 29% in
2006 to 39% in 2008 (p,.0001) (Figure 1). Incomplete data in key
fields (e.g. name and date of birth) affected the matching of some
reports to the surveillance registry. However, the proportion of
resistance tests that could be matched was similar to other
reportable tests.
The completeness and accuracy of risk ascertainment is an
ongoing challenge for surveillance. Misclassification of heterosex-
Figure 1. Proportion of cases receiving genotype within 3 months of diagnosis, with adjustment for completeness of reporting.
doi:10.1371/journal.pone.0040533.g001
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ual transmission as NIR and misclassification of MSM as
heterosexual may account for our observations of reduced risk
associated with NIR and equivalent risk in MSM and heterosex-
uals [41].
Our TDR estimate may be biased because it is based on
genotypes for less than one-third of persons with new diagnoses
and less than one-half of those initiating care within 3 months. It is
possible that TDR in persons not genotyped is significantly
different from the TDR patterns reported here. In addition, our
estimate may under-represent clinically important resistance;
minority quasispecies, not detectable by genotypes reported to
NYSDOH, have been shown to be prevalent in untreated persons
and to reduce treatment efficacy [42]. Finally, current reporting
does yet not allow the monitoring of resistance certain classes of
ARVs including integrase strand-transfer inhibitors, entry inhib-
itors or CCR5 receptor antagonists.
Conclusion
Using the New York State HIV resistance surveillance system,
we have taken an important step in addressing transmitted drug
resistance as a public health concern. In contrast to earlier local
reports, our data suggest that TDR is not increasing and that
multiclass TDR is not prevalent. Furthermore, TDR is not isolated
to a specific subgroup, and common starting regimens are still
effective for most new diagnoses in New York State. This
information will help shape our response to the epidemic in both
the public health and medical communities.
This analysis suggests that continuing routine resistance
surveillance is appropriate for three reasons. First, more data are
needed to verify the trend in TDR. Resistance surveillance systems
such as the one describe here are uniquely qualified to provide
consistent, long-term monitoring. Methodological differences
between short-term studies make it difficult to evaluate trends in
TDR. Second, treatment-intensive community strategies such as
‘Test and Treat’ and PrEP may increase TDR. Third, in contrast
to surveillance based on specimen salvage, which is costly and
logistically difficult, resistance surveillance through routine elec-
tronic reporting is relatively low cost and scalable. If improved
TDR estimation is found to be necessary, routine reporting could
be supplemented with specimen salvage from new diagnoses
without routine genotype results.
This work illustrates the power of surveillance to establish
baselines and monitor progress toward goals established to achieve
epidemic mitigation and control [43]. However, broader provider
uptake of genotype testing is needed to better estimate population
TDR and to understand the TDR prevalence at which routine
genotyping and surveillance of new diagnoses provide clinically
and epidemiologically significant information.
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